NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $8.50, above its previous 52-week high of $8.47 with 98,310 shares traded as of 11:01 a.m. ET. Average volume has been 339,900 shares over the past 30 days.
Endologix has a market cap of $477.9 million and is part of the
industry. Shares are up 17.8% year to date as of the close of trading on Friday.
Endologix, Inc. develops, manufactures, markets, and sells minimally invasive treatments for aortic disorders. Its flagship product, the Powerlink System, is an endovascular stent graft for the treatment of abdominal aortic aneurysms, a weakening of the wall of the aorta, an artery in the body. The company has a P/E ratio of 168.4, above the average health services industry P/E ratio of 70.2 and above the S&P 500 P/E ratio of 17.7.
- Practice your ELGX trading strategies and win cash in our stock game.
TheStreet Ratings rates Endologix as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, premium valuation and feeble growth in the company's earnings per share. You can view the full
52-week high stocks
or get investment ideas from our